← Back to headlines
Pfizer's Ibrance Receives FDA Label Expansion for Breast Cancer Drug
Pfizer has been granted an FDA label expansion for its breast cancer drug, Ibrance.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
